252 related articles for article (PubMed ID: 25492236)
81. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M;
Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042
[TBL] [Abstract][Full Text] [Related]
82. Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.
Yan X; Zhou M; Lou Z; Mu Q; Sheng L; Zhang P; Wang Y; Ouyang G
J Cancer Res Ther; 2018; 14(Supplement):S248-S253. PubMed ID: 29578182
[TBL] [Abstract][Full Text] [Related]
83. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
84. Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores.
Lee H; Kim YR; Kim SJ; Park Y; Eom HS; Oh SY; Kim HJ; Kang HJ; Lee WS; Moon JH; Won YW; Kim TS; Kim JS
Ann Hematol; 2017 Nov; 96(11):1873-1881. PubMed ID: 28831584
[TBL] [Abstract][Full Text] [Related]
85. Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab.
Chaiwatanatorn K; Stamaratis G; Opeskin K; Firkin F; Nandurkar H
Leuk Lymphoma; 2009 Oct; 50(10):1666-75. PubMed ID: 19757311
[TBL] [Abstract][Full Text] [Related]
86. Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era.
Hasselblom S; Stenson M; Werlenius O; Sender M; Lewerin C; Hansson U; Nilsson-Ehle H; Andersson PO
Leuk Lymphoma; 2012 Mar; 53(3):394-9. PubMed ID: 21864039
[TBL] [Abstract][Full Text] [Related]
87. The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era.
Chen H; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Gui L; Yang S; Shi Y
Leuk Res; 2021 Nov; 110():106715. PubMed ID: 34598076
[TBL] [Abstract][Full Text] [Related]
88. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.
Williams JN; Rai A; Lipscomb J; Koff JL; Nastoupil LJ; Flowers CR
Cancer; 2015 Jun; 121(11):1800-8. PubMed ID: 25675909
[TBL] [Abstract][Full Text] [Related]
89. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
90. Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy.
Li C; Ma X; Pan Z; Lv F; Xia Z; Xue K; Zhang Q; Ji D; Cao J; Hong X; Guo Y
Leuk Res; 2018 Nov; 74():80-85. PubMed ID: 30316031
[TBL] [Abstract][Full Text] [Related]
91. ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.
Kim IS; Kim HG; Kim DC; Eom HS; Kong SY; Shin HJ; Hwang SH; Lee EY; Lee GW
Cancer Sci; 2008 Dec; 99(12):2496-501. PubMed ID: 19032367
[TBL] [Abstract][Full Text] [Related]
92. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
Ennishi D; Yokoyama M; Terui Y; Asai H; Sakajiri S; Mishima Y; Takahashi S; Komatsu H; Ikeda K; Takeuchi K; Tanimoto M; Hatake K
Ann Oncol; 2009 Mar; 20(3):526-33. PubMed ID: 19074749
[TBL] [Abstract][Full Text] [Related]
93. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
[TBL] [Abstract][Full Text] [Related]
94. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
95. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).
Gratzinger D; Advani R; Zhao S; Talreja N; Tibshirani RJ; Shyam R; Horning S; Sehn LH; Farinha P; Briones J; Lossos IS; Gascoyne RD; Natkunam Y
Br J Haematol; 2010 Jan; 148(2):235-44. PubMed ID: 19821819
[TBL] [Abstract][Full Text] [Related]
96. How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.
Huang BT; Zeng QC; Yu J; Xiao Z; Li BS; Zhang CL; Ji HB
J Cancer Res Clin Oncol; 2012 Jan; 138(1):125-32. PubMed ID: 22057732
[TBL] [Abstract][Full Text] [Related]
97. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
Oki Y; Westin JR; Vega F; Chuang H; Fowler N; Neelapu S; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale M; Younes A; Rodriguez MA; Orlowski RZ; Wang M; Ouzounian ST; Samaniego F; Fayad L
Br J Haematol; 2013 Dec; 163(5):611-20. PubMed ID: 24117234
[TBL] [Abstract][Full Text] [Related]
98. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
[TBL] [Abstract][Full Text] [Related]
99. Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era.
Gutierrez A; Bento L; Diaz-Lopez A; Barranco G; Garcia-Recio M; Lopez-Guillermo A; Dlouhy I; Rovira J; Rodriguez M; Sanchez Pina JM; Baile M; Martín A; Novelli S; Sancho JM; García O; Salar A; Bastos-Oreiro M; Rodriguez-Salazar MJ; Fernandez R; de la Cruz F; Queizan JA; González de Villambrosia S; Cordoba R; López A; Luzardo H; García D; Sastre-Serra J; Garcia JF; Montalban C; Cabanillas F; Rodríguez J
Eur J Haematol; 2020 May; 104(5):400-408. PubMed ID: 31804029
[TBL] [Abstract][Full Text] [Related]
100. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.
Hong F; Habermann TM; Gordon LI; Hochster H; Gascoyne RD; Morrison VA; Fisher RI; Bartlett NL; Stiff PJ; Cheson BD; Crump M; Horning SJ; Kahl BS
Ann Oncol; 2014 Mar; 25(3):669-674. PubMed ID: 24567515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]